Literature DB >> 19856663

Changes in expression of bile canalicular CD10 and sinusoidal CD105 (endoglin) in peritumoral hepatic tissue.

Toshitsugu Nakamura1.   

Abstract

UNLABELLED: AIMS AND BACKGROUND; Hepatic tissues, including bile canaliculi and sinusoids, around primary or metastatic tumors are destructed and regenerate associated with tumor growth, and may show some phenotypic changes. The present study was undertaken to examine the expression of CD10 in bile canaliculi [CD10(BC)] and CD105 (endoglin) along hepatic sinusoids [CD105(HS)] in peritumoral hepatic tissue (PTH).
METHODS: Fifty samples of resected liver bearing hepatocellular carcinoma (HCC) or metastatic carcinoma were immunostained for CD10 and CD105. The immunoreactivity for CD10(BC) and CD105(HS) in the background hepatic tissue of tumors and PTH was scored separately.
RESULTS: CD10(BC) was moderately or markedly expressed in the background hepatic tissue without chronic hepatitis or cirrhosis in most of the cases, and was significantly downregulated in chronic hepatitis and cirrhosis. CD105(HS) was negative or minimally positive in most of the cases of hepatic tissue bearing metastatic carcinoma, and showed a significant increase in chronic hepatitis and cirrhosis. Compared with the background, PTH revealed significantly decreased CD10(BC) staining irrespective of HCC or metastatic carcinoma, and showed belt-like CD105(HS) expression in 66.7% of the cases of metastatic carcinoma and in 88.6% of those with HCC.
CONCLUSIONS: These data indicate that the expression patterns of CD10(BC) and CD105(HS) in PTH are similar to those in chronic hepatitis and cirrhosis, which may be caused by persistent injury and resultant regeneration of hepatic tissue.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19856663     DOI: 10.1177/030089160909500415

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  6 in total

1.  Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth.

Authors:  Fanyin Meng; Sharon DeMorrow; Julie Venter; Gabriel Frampton; Yuyan Han; Heather Francis; Holly Standeford; Shanika Avila; Kelly McDaniel; Matthew McMillin; Syeda Afroze; Micheleine Guerrier; Morgan Quezada; Debolina Ray; Lindsey Kennedy; Laura Hargrove; Shannon Glaser; Gianfranco Alpini
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-03-06       Impact factor: 4.052

2.  Evaluation and comparison of microvessel density using the markers CD34 and CD105 in regenerative nodules, dysplastic nodules and hepatocellular carcinoma.

Authors:  Vanderlei Segatelli; Ebe Christie de Oliveira; Ilka F S F Boin; Elaine Cristina Ataide; Cecilia Amelia F Escanhoela
Journal:  Hepatol Int       Date:  2014-03-02       Impact factor: 6.047

3.  Microvascular density of regenerative nodule to small hepatocellular carcinoma by automated analysis using CD105 and CD34 immunoexpression.

Authors:  Juliana Passos Paschoal; Vagner Bernardo; Nathalie Henriques Silva Canedo; Osmar Damasceno Ribeiro; Adriana Caroli-Bottino; Vera Lucia Pannain
Journal:  BMC Cancer       Date:  2014-02-07       Impact factor: 4.430

4.  Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis: correlation with pathological features.

Authors:  Osmar Damasceno Ribeiro; Nathalie Henriques Silva Canedo; Vera Lucia Pannain
Journal:  Clinics (Sao Paulo)       Date:  2016-11-01       Impact factor: 2.365

5.  Antifibrotic Effects of Amyloid-Beta and Its Loss in Cirrhotic Liver.

Authors:  Gayane Hrachia Buniatian; Ralf Weiskirchen; Thomas S Weiss; Ute Schwinghammer; Martin Fritz; Torgom Seferyan; Barbara Proksch; Michael Glaser; Ali Lourhmati; Marine Buadze; Erawan Borkham-Kamphorst; Frank Gaunitz; Christoph H Gleiter; Thomas Lang; Elke Schaeffeler; Roman Tremmel; Holger Cynis; William H Frey; Rolf Gebhardt; Scott L Friedman; Wolfgang Mikulits; Matthias Schwab; Lusine Danielyan
Journal:  Cells       Date:  2020-02-17       Impact factor: 6.600

6.  CD105 is a prognostic marker and valid endothelial target for microbubble platforms in cholangiocarcinoma.

Authors:  Amit Nair; Nicola Ingram; Eldo T Verghese; Imeshi Wijetunga; Alexander F Markham; Judy Wyatt; K Rajendra Prasad; P Louise Coletta
Journal:  Cell Oncol (Dordr)       Date:  2020-05-28       Impact factor: 6.730

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.